We are live on ! Find out more
ACHL

Achilles Therapeutics
ACHL

Delisted

ACHL was delisted on the 20th of March, 2025.

Back to rankings

3 hedge funds and large institutions have $98.9K invested in Achilles Therapeutics in 2026 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

85% more capital invested

Capital invested by funds: $53.3K → $98.9K (+$45.5K)

0% more funds holding

Funds holding: 3 → 3 (0)

Holders
3
Holders Change
–
Holders Change %
0%
% of All Funds
0.04%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TC
Trium Capital
United Kingdom
+$45.5K

Top Sellers

No sellers this quarter

ACHL Hedge Fund Activity: Q2 2026 in Review

3 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Achilles Therapeutics (ACHL) for Q2 2026, worth a combined $98.9K — up 85% from $53.3K a quarter earlier.

Fund positioning in ACHL was balanced in Q2 2026: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Trium Capital, adding an estimated $45.5K.

  • 3 institutional investors held Achilles Therapeutics (ACHL) as of Q2 2026, unchanged from Q1 2026.
  • Funds reported $98.9K of Achilles Therapeutics stock for Q2 2026, up 85% quarter-over-quarter.
  • 0 funds opened new Achilles Therapeutics positions in Q2 2026 and 0 closed out.
  • The largest Achilles Therapeutics buyer in Q2 2026 was Trium Capital, an estimated $45.5K added.

Based on aggregated 13F filings for Q2 2026.